Business
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research
Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health ResearchToronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Corporation\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been awarded a seven-figure, five-year grant from the Canadian Institutes of Health Research (CIHR). The grant entitled \"Muscle Stem Cell Function in Duchenne Muscular Dystrophy\" was awarded by the Genetics Research Panel. The $1,071,000 grant will support the research led by Dr. Rudnicki at the Ottawa Hospital Research Institute to investigate the molecular pathobiology in muscle stem cells that contributes to disease progression in Duchenne muscular dystrophy (\"Duchenne\").Dr. Rudnicki made the paradigm shifting discovery that loss of polarity control in muscle stem cells is a major driver of disease in Duchenne and resulted in his appointment to the Royal Society (London). Extending these studies is the subject of the research being supported by this new grant from the Canadian Institutes of Health Research. Dr. Rudnicki's discovery also underpins the drug development efforts underway at Satellos Bioscience that is targeting polarity control in stem cells to enhance regeneration as a treatment for Duchenne and other muscle disorders.\"Deemed the number one ranked genetics panel proposal, this award further exemplifies the scientific community's excitement and strong support for pursuing the understanding of stem cell function in Duchenne,\" said Satellos Co-Founder and CEO, Frank Gleeson. \"We're proud to have Michael as a central part of the Satellos team, and excited to celebrate the high profile and deserved accolades he and his work continue to receive.\" Along with his role as Co-founder and CSO with Satellos, Dr. Rudnicki is a Senior Scientist and Director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute - the research arm of The Ottawa Hospital. The Canadian Institutes of Health Research is Canada's federal funding agency for health research. Compo...